Eosinophilic vacuolated tumor of kidney: a clinical case and literature review

Renal cell cancer ranks 8th in the world among all oncological diseases. The most common are clear cell, papillary, and chromophobe subtypes. Due to the development of clinical, morphological, and molecular genetic diagnostic methods, the current classification of renal cell cancer has undergone significant changes. A clinical case of a patient with an eosinophilic vacuolated tumor of kidney is presented. A special feature of this case is the rarity of this subtype of kidney cancer: currently, no more than 100 clinical cases have been described in the world. At the time of writing, the follow-up period is more than 18 months; the patient undergoes periodic examinations, and there is no data for tumor recurrence.

Authors

Publication Details

Journal
Hirurg (Surgeon)
Published
2025-03-22
DOI
https://doi.org/10.33920/med-15-2502-06
Primary Topic
Tuberous Sclerosis Complex Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Eosinophilic vacuolated tumor of kidney: a clinical case and literature review

Leonid T. Savin, А. А. Грицкевич, Gennadii Kochetov, T. P. Baitman et al.
Hirurg (Surgeon)
Tuberous Sclerosis Complex Research
article

Eosinophilic vacuolated tumor of kidney: a clinical case and literature review

Leonid T. Savin, А. А. Грицкевич, Gennadii Kochetov, T. P. Baitman, A.A. Savina, Daniil Parhomenko, I. A. Esipov
article en

Abstract

Renal cell cancer ranks 8th in the world among all oncological diseases. The most common are clear cell, papillary, and chromophobe subtypes. Due to the development of clinical, morphological, and molecular genetic diagnostic methods, the current classification of renal cell cancer has undergone significant changes. A clinical case of a patient with an eosinophilic vacuolated tumor of kidney is presented. A special feature of this case is the rarity of this subtype of kidney cancer: currently, no more than 100 clinical cases have been described in the world. At the time of writing, the follow-up period is more than 18 months; the patient undergoes periodic examinations, and there is no data for tumor recurrence.

Hirurg (Surgeon)(2)
Openalex Percentile: Top 90%
Tuberous Sclerosis Complex Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.